[1] SALATA O V. Applications of nanoparticles in biology and medicine . J Nanobiotechnol, 2004, 2(1): 3-8.[2] SOPPIMATH K S, AMINABHAVI T M, KULKARNI A R, et al. Biodegradable polymeric nanoparticles as drug delivery devices . J Controlled Release, 2001, 70(1): 1-20.[3] JIN L X. Research and clinical application of nano-drug carriers. J Clin Rehabilitative Tissue Engineering Res(中国组织工程研究与临床康复), 2010, 14(8): 1429-1432.[4] BRIGGER I, DUBERNET C, COUVREUR P. Nanoparticles in cancer therapy and diagnosis . Adv Drug Deliv Rev, 2002, 54: 631-651.[5] DE M, GHOSH P S, ROTELLO V M. Applications of nanoparticles in biology . Adv Mater, 2008, 20(22): 4225-4241.[6] DAWES J, PEPPER D S. Catabolism of low-dose heparin in man . Thromb Res, 1979, 14(6): 845-860.[7] GARG H G, ROUGHLEY P J, HALES C A. Proteoglycans in Lung Disease. New York, Basel: Marcel Dekker Inc, 2003: 377-398.[8] HIRSH J, WARKENTIN T E, SHAUGHNESSY S G, et al. Heparin and low-molecular-weight heparin-mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest, 2001, 119(suppl 1): 64-94. [9] CAPILA I, LINHARDT R J. Heparin-protein interactions. Angew Chem Int Ed, 2002, 41(3): 390-412. WANG L, BROWN J R, VARKI A, et al. Heparin′s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockage of L- and P-selectins . J Clin Invest, 2002, 110(1): 127-136. BORSIG L, WONG R, FERAMISCO J, et al. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis . PNAS, 2011, 98(6): 3352-3357. VLODAVSKYA I, ILANA N, NADIRA Y, et al. Heparanase, heparin and the coagulation system in cancer progression . Thromb Res, 2007, 120(suppl 2): 112-120. YAYON A, KLAGSBRUN M, ESKO J D, et al. Cell Surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor . Cell, 1991, 64(1): 841-848. GITAY-GOREN H, SOKER S, VLODAVSKY I, et al. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules . J Biol Chem, 1992, 267(9): 6093-6098. TAO J, CHEN Y, XIONG F, et al. Magnetic nanoparticles and their application in drug delivery system . Prog Pharm Sci(药学进展),2010, 34(4): 145-151. KE X, DENG L, CHEN J. Research progress of superparamagnetic iron oxide nanoparticles in drug delivery system. Pharm Clin Res(药学与临床研究), 2011, 19(3): 257-261. KHURSHID H, KIM S H, BONDER M J, et al. Development of heparin-coated magnetic nanoparticles for targeted drug delivery applications . J Applied Physics, 2009, 105(07):308. MIN K A, YU F, YANG V C, et al. Transcellular transport of heparin-coated magnetic iron oxide nanoparticles(Hep-MION) under the influence of an applied magnetic field . Pharmaceutics,2010, 2(2): 119-135. LEE D Y. Highly effective T2 MR contrast agent based on heparinized superparamagnetic iron oxide nanoparticles . Macromolecular Res, 2011, 19(8): 843-847. YUK S H, OH K S, CHO S H, et al. Glycol chitosan/heparin immobilized iron oxide nanoparticles with a tumor-targeting characteristic for magnetic resonance imaging . Biomacromolecules,2011, 12(6): 2335-2343. HWANG J H, LEE S, KIM E, et al. Heparin-coated superparamagnetic nanoparticle-mediated adeno-associated virus delivery for enhancing cellular transduction . Int J Pharmaceut,2011, 421(2): 397- 404. JAIN P K, HUANG X H, EL-SAYED I H, et al. Noble metals on the nanoscale: Optical and photothermal properties and some applications in imaging, sensing, biology, and medicine . Accounts Chem Res, 2008, 41(12): 1578-1586 . LEE K, LEE H, BAE K H, et al. Heparin immobilized gold nanoparticles for targeted detection and apoptotic death of metastatic cancer cells . Biomaterials, 2010, 31(25): 6530-6536. CHUNG Y I, KIMA J C, KIM Y H, et al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting . J Controlled Release, 2010, 143(3): 374-382. CHUNG Y I, TAE G, YUK S H. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors . Biomaterials, 2006, 27: 2621-2626. CHUNG Y I, KIMC S K, LEE Y K, et al. Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex . J Controlled Release, 2010, 143(3): 282-289. CHAUVIERRE C, MARDENB M C, VAUTHIER C, et al. Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: A new oxygen carrier . Biomaterials, 2004, 25(15): 3081-3086. UVIERRE C, MANCHANDA R, LABARRE D, et al. Artificial oxygen carrier based on polysaccharides-poly(alkylcyanoacrylates) nanoparticle templates . Biomaterials, 2010, 31: 6069-6074. SOCHA M, BARTECKI P, PASSIRANI C, et al. Stealth nanoparticles coated with heparin as peptide or protein carriers . J Drug Targeting, 2009, 17(8): 575-585. WILEY S R, SCHOOLEY K, SMOLAK P J, et al. Identification and characterization of a new member of the TNF family that induces apoptosis . Immunity, 1995, 3(6):673-662 . KIM Y J, CHAE S Y, JIN C H, et al. In vitro characteristics of heparin/tumor necrosis factor-related apoptosis-inducing ligand nanocomplexes . Mol Cryst Liq Cryst, 2009, 508(1): 91/ -100/. ZENG H, ZHANG H, HUANG K, et al. Advances in pharmaceutical research of basic fibroblast growth factor . Chin J New Drugs(中国新药杂志), 2010, 19(11): 949-952. TANG D W, YU S H, HO Y C, et al. Heparinized chitosan/poly(γ-glutamic acid) nanoparticles for multi-functional delivery of fibroblast growth factor and heparin . Biomaterials, 2010, 31(35): 9320-9332. PARK K H, KIM H, KUN N A. Neuronal differentiation of PC12 cells cultured on growth factor-loaded nanoparticles coated on PLGA microspheres . J Microbiol Biotechnol, 2009, 19(11): 1490-1495. MORI Y, NAKAMURA S, KISHIMOTO S, et al. Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles(LMW-h/P NPs) as FGF-2 carrier . Int J Nanomedicine, 2010, 5: 147-155. MOGHIMI S M, HUNTER A C, MURRAY J C. Long-circulating and target-specific nanoparticles: Theory to practice . Pharmacol Rev, 2001, 53(2):283-318. PARK K, LEE G Y, KIM Y S, et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity . J Controlled Release, 2006, 114(3): 300-306. WANG Y, XIN D C, LIU K J, et al. Heparin paclitaxel conjugates as drug delivery system: Synthesis, self-assembly property, drug release, and antitumor activity . Bioconjugate Chem, 2009, 20(12): 2214-2221. HOU L, FAN Y, YAO J, et al. Low molecular weight heparin-all-trans-retinoid acid conjugate as a drug carrier for combination cancer chemotherapy of paclitaxel and all-trans-retinoid acid . Carbohydrate Polymers, 2011, 86(3): 1157-1166. PARKA I K, TRANA T H, OHA I H, et al. Ternary biomolecular nanoparticles for targeting of cancer cells and anti-angiogenesis . Eur. J Pharmaceutical Sci, 2010, 41(1): 148-155. WANG X, LI J, WANG Y, et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors . ACSNANO, 2009, 3(10): 3165-3174. WANG X, LI J, WANG Y, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model . ACSNANO, 2011, 5(8): 6184-6194. LI L, HUH K M, LEE Y K, et al. Biofunctional self-assembled nanoparticles of folate-PEG-heparin/PBLA copolymers for targeted delivery of doxorubicin. J Mater Chem, 2011, 21(39): 15288-15297 . LI L, MOON H T, PARK J Y, et al. Heparin-based self-assembled nanoparticles for photodynamic therapy . Macromolecular Res, 2011, 19(5) 487-494 . CHANG C H, HUANG W Y, LAI C H, et al. Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori . Acta Biomaterialia, 2011, 7(12): 593-603. BAE K H, MOK H, PARK T G. Synthesis, characterization, and intracellular delivery of reducible heparin nanogels for apoptotic cell death . Biomaterials, 2008, 29(23): 3376-3383.